1248541-63-0

Usage

Uses

Methyl 2,3-diamino-5-bromobenzoate

Upstream product

• 636581-61-8 2-amino-5-bromo-3-nitrobenzoic acid methyl ester 
• 49764-59-2 5-bromo-7-nitro-1H-indole-2,3-dione 
• 87-48-9 5-Bromo-1H-indole-2,3-dione 
• 57113-91-4 methyl 3-nitroanthranilate 
• 58580-07-7 2-amino-5-bromo-3-nitro-benzoic acid 

Downstream Products

• 861259-02-1 6-bromo-2-(2,3-dichloro-phenylamino)-3H-benzoimidazole-4-carboxylic acid methyl ester 

Relevant academic research and scientific papers

1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS

The present invention provides 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitor compounds of formula (I), which may be therapeutically useful as DHODH inhibitors, in which R1 to R3

COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

SUBSTITUTED QUINOXALINE DERIVATIVES

The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS

This application relates to chemical compounds which may act as inhibitors of; or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2, R2b, R3, R4a, R4b, and R5 are described herein.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

ORGANIC COMPOUNDS

Compounds of formula (I) in free or salt form, where Y, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the CXCR2 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.